I am the originator of the AAV gene therapy technology while at the University of Florida (two major publications in 1984), having identified and located the main genes of AAV (rep and cap), determined their functions, cloned Rep78 gene to produce and study of the Rep78 protein in detail, generated the first platform for rAAV/virus production by elongating the AAV2 genome by 1.5kb, used this platform to generate AAV2/NeoR virus which converted D6 cells into being G418 resistant, and the first rAAV/NeoR gene transfer experiment is on the cover of Human Gene Therapy in 2014.  After this at the Univ Ark Med Sci I used various rAAV2, rAAV6, rAAV8, etc. vectors to transfer various cancer antigen genes into dendritic cells to stimulate CD8 and CD4 cytotoxic T lymphocytes that could kill those specific cancer cells, and then moved on to the treatment of atherosclerosis using a variety of anti-inflammatory genes, plus I am far from done on this job, which I will cover about in my talk, now as CEO of Houston Gene Therapeutics, Inc.